Q32 Bio Inc.
QTTB
$6.30
-$0.52-7.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -70.85% | -36.95% | 55.62% | 6.53% | -19.84% |
| Gross Profit | 282.13% | 61.35% | 12.74% | 23.92% | 33.73% |
| SG&A Expenses | -1.56% | 1.97% | 21.02% | 44.87% | 81.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.67% | -32.12% | 0.46% | 35.63% | 58.88% |
| Operating Income | 126.97% | 44.98% | 18.92% | -12.27% | -36.98% |
| Income Before Tax | 162.50% | 30.29% | 7.84% | -31.20% | 10.69% |
| Income Tax Expenses | -- | -91.70% | -93.40% | -93.40% | -93.40% |
| Earnings from Continuing Operations | 162.47% | 30.54% | 8.31% | -30.34% | 11.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 162.47% | 30.54% | 8.31% | -30.34% | 11.18% |
| EBIT | 126.97% | 44.98% | 18.92% | -12.27% | -36.98% |
| EBITDA | 127.76% | 45.18% | 19.00% | -12.40% | -37.40% |
| EPS Basic | 176.79% | 95.59% | 96.33% | 96.27% | 98.04% |
| Normalized Basic EPS | 134.43% | 92.31% | 94.47% | 94.65% | 96.85% |
| EPS Diluted | 122.18% | 95.97% | 96.54% | 96.46% | 93.24% |
| Normalized Diluted EPS | 130.04% | 92.39% | 94.50% | 94.68% | 96.41% |
| Average Basic Shares Outstanding | 32.20% | 92.26% | 256.16% | 2,268.95% | 2,571.30% |
| Average Diluted Shares Outstanding | 27.68% | 82.63% | 224.37% | 1,331.33% | 2,667.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |